Literature DB >> 29373707

Cardiovascular and cerebrovascular comorbidities of juvenile dermatomyositis in US children: an analysis of the National Inpatient Sample.

Jonathan I Silverberg1, Lauren Kwa2, Michael C Kwa2, Anne E Laumann2, Kaveh Ardalan3.   

Abstract

Objective: JDM is associated with multiple potential risk factors for cardiovascular disease, including reduced heart rate variability, systolic/diastolic cardiac dysfunction, abnormal brachial artery reactivity and metabolic syndrome. However, little is known about cardiovascular risk in JDM. We sought to examine the association between JDM and cardiovascular risk factors and disease in US children.
Methods: Data from the 2002-12 National Inpatient Sample was analysed, including ∼20% of all US hospitalizations (n = 14 535 620 paediatric hospitalizations).
Results: JDM was significantly associated with 12 of 13 comorbidities, including hypertension [survey logistic regression; crude odds ratio (95% CI): 22.25 (15.51, 31.92)], obesity [5.87 (3.44, 10.02)], uncomplicated diabetes [7.95 (4.21, 15.00)], lipid abnormalities [5.84 (2.77, 12.31)], particularly lipodystrophy [151.08 (38.24, 596.86)], peripheral and visceral atherosclerosis [10.09 (3.70, 27.56)], late effects of cerebrovascular disease [15.49 (2.37, 101.43)], personal history of transient ischaemic attack and cerebral infarction [10.82 (2.46, 47.65)], pulmonary circulatory disorder [12.23 (2.59, 57.73)], arrhythmia [3.93 (2.80, 5.52)], bradycardia [4.22 (2.65, 6.74)] and hypotension [2.62 (1.27, 5.39)]. Conclusions: There are significantly higher odds of cardiovascular and cerebrovascular comorbidities among inpatients with JDM, with adolescents, girls and racial/ethnic minorities being at highest risk.

Entities:  

Mesh:

Year:  2018        PMID: 29373707     DOI: 10.1093/rheumatology/kex465

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  13 in total

Review 1.  Aminoquinoline antimalarial therapy in dermatomyositis-are we missing opportunities with respect to comorbidities and modulation of extracutaneous disease activity?

Authors:  Richard D Sontheimer
Journal:  Ann Transl Med       Date:  2018-04

2.  Inpatient burden of juvenile dermatomyositis among children in the United States.

Authors:  Michael C Kwa; Jonathan I Silverberg; Kaveh Ardalan
Journal:  Pediatr Rheumatol Online J       Date:  2018-11-13       Impact factor: 3.054

Review 3.  Systemic and Tissue Inflammation in Juvenile Dermatomyositis: From Pathogenesis to the Quest for Monitoring Tools.

Authors:  Judith Wienke; Claire T Deakin; Lucy R Wedderburn; Femke van Wijk; Annet van Royen-Kerkhof
Journal:  Front Immunol       Date:  2018-12-18       Impact factor: 7.561

4.  Epilepsy as a Comorbidity in Polymyositis and Dermatomyositis-A Cross-Sectional Study.

Authors:  Ella Nissan; Abdulla Watad; Arnon D Cohen; Kassem Sharif; Johnatan Nissan; Howard Amital; Ora Shovman; Nicola Luigi Bragazzi
Journal:  Int J Environ Res Public Health       Date:  2021-04-10       Impact factor: 3.390

5.  Transcriptomes of peripheral blood mononuclear cells from juvenile dermatomyositis patients show elevated inflammation even when clinically inactive.

Authors:  Elisha D O Roberson; Rosana A Mesa; Gabrielle A Morgan; Li Cao; Wilfredo Marin; Lauren M Pachman
Journal:  Sci Rep       Date:  2022-01-07       Impact factor: 4.379

6.  Characteristics of hospitalized dermatomyositis patients with underlying malignancy: a nationally representative retrospective cohort study.

Authors:  Raghav Tripathi; Anthony P Fernandez
Journal:  Arch Dermatol Res       Date:  2020-08-17       Impact factor: 3.017

Review 7.  The Vasculopathy of Juvenile Dermatomyositis.

Authors:  Charalampia Papadopoulou; Liza J McCann
Journal:  Front Pediatr       Date:  2018-10-09       Impact factor: 3.418

8.  Assessment of traditional and non-traditional risk factors for premature atherosclerosis in children with juvenile dermatomyositis and pediatric controls.

Authors:  Dawn M Wahezi; Emily J Liebling; Jaeun Choi; Marija Dionizovik-Dimanovski; Qi Gao; Jillian Parekh
Journal:  Pediatr Rheumatol Online J       Date:  2020-03-18       Impact factor: 3.054

9.  Dermatomyositis presenting as heart failure revealed a concealed cervical malignancy: an infrequent clinical nexus.

Authors:  Ritwik Ghosh; Souvik Dubey; Subhankar Chatterjee; Rakesh Biswas
Journal:  BMJ Case Rep       Date:  2020-02-28

10.  Juvenile Dermatomyositis: New Clues to Diagnosis and Therapy.

Authors:  Lauren M Pachman; Brian E Nolan; Deidre DeRanieri; Amer M Khojah
Journal:  Curr Treatm Opt Rheumatol       Date:  2021-02-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.